ClinicalTrials.gg
WithdrawnNCT03704077Updated May 19, 2020

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

A Phase 2 interventional study of Relatlimab + Nivolumab and Nivolumab in Gastric Cancer, Cancer of the Stomach and Stomach Cancer, sponsored by Bristol-Myers Squibb. Withdrawn at 84 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-19.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Replaced it with another clinical trial

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing nivolumab in Stomach Neoplasms — 6 open to participants now, 13 under way, 2 of them phase 3. Nivolumab · Stomach Neoplasms.

Enrollment
30th of 30
0 · median 49
Started
2019
with 3 others
Phase 2
14 of 30
4 open now
Registered
12th of 30
by date
Lead sponsor
2 of 30
Bristol-Myers Squibb

Among the 30 studies testing nivolumab in Stomach Neoplasms, this one is the 30th largest by enrollment, is one of 4 that started in 2019, is one of 14 in phase 2, and was the 12th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

6 of the 30 studies testing nivolumab in Stomach Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing nivolumab in Stomach Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine the effectiveness of relatlimab plus nivolumab, alone or in combination with various standard-of-care treatments in participants with gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma that has come back or spread to other places in the body after prior therapy.

03

Conditions studied

  • Gastric Cancer
  • Cancer of the Stomach
  • Stomach Cancer
  • Gastroesophageal Junction

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • or cytologically confirmed locally advanced or recurrent or GC or GEJ adenocarcinoma that is considered incurable by local therapies such as radiation or surgery
  • Evidence of progressive disease (PD) on at least one prior platinum- and fluoropyrimidine-containing chemotherapy regimen
  • Available tumor tissue for biomarker analysis

Exclusion criteria

Exclusion Criteria:

  • Must not have squamous cell or undifferentiated GC or GEJ
  • Untreated known central nervous system (CNS)
  • Uncontrolled or significant cardiovascular disease

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Cohort A: relatlimab + nivolumab + paclitaxel

    Biological: Relatlimab + Nivolumab · Biological: Nivolumab · Drug: Paclitaxel

  • Experimental
    Cohort A: nivolumab + paclitaxel

    Biological: Nivolumab · Drug: Paclitaxel

  • Active comparator
    Cohort A: ramucirumab + paclitaxel

    Standard-of-care

    Drug: Paclitaxel · Drug: Ramucirumab

  • Experimental
    Cohort B: relatlimab + nivolumab

    Biological: Relatlimab + Nivolumab · Biological: Nivolumab

  • Active comparator
    Cohort B: nivolumab

    Standard-of-care

    Biological: Nivolumab

  • Experimental
    Cohort C: relatlimab + nivolumab

    Biological: Relatlimab + Nivolumab · Biological: Nivolumab

Interventions

  • BiologicalRelatlimab + Nivolumab

    Drug pages: Relatlimab · Nivolumab

    Specified dose on specified days

    Also known as: BMS-986213

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: Opdivo

  • Specified dose on specified days

    Also known as: Taxol, Onxal

  • Specified dose on specified days

    Also known as: Cyramza

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR)

    Time frame: Approximately 31 months

Secondary outcomes

  1. Incidence of adverse events (AEs)

    Time frame: Approximately 5 years

  2. Incidence of serious adverse events (SAEs)

    Time frame: Approximately 5 years

  3. Incidence of AEs leading to discontinuation

    Time frame: Approximately 5 years

  4. Incidence of deaths

    Time frame: Approximately 5 years

  5. Incidence of laboratory abnormalities

    Time frame: Approximately 5 years

  6. ORR

    Cohort A1

    Time frame: Approximately 5 years

  7. Duration of response (DOR)

    Time frame: Approximately 5 years

  8. Progression free survival (PFS)

    Time frame: Approximately 5 years

  9. Overall survival (OS)

    Time frame: Approximately 5 years

07

Study locations

84 sites
  • Local Institution
    Daphne, Alabama 36526, United States
  • Local Institution
    Bakersfield, California 93309, United States
  • Local Institution
    Fullerton, California 92835, United States
  • Local Institution
    Los Angeles, California 90095, United States
  • Local Institution
    Redondo Beach, California 90277, United States
  • Local Institution
    Santa Barbara, California 93105, United States
  • Local Institution
    Aurora, Colorado 80045, United States
  • Local Institution
    Lakewood, Colorado 80228, United States
  • Local Institution
    Miami, Florida 33176, United States
  • Local Institution
    Tampa, Florida 33612, United States
  • Local Institution
    Marietta, Georgia 30060, United States
  • Local Institution
    Boston, Massachusetts 02215, United States
  • Local Institution
    Saint Louis, Missouri 63110, United States
  • Local Institution
    New Brunswick, New Jersey 08009, United States
  • Local Institution
    Chapel Hill, North Carolina 27599, United States
  • Local Institution
    Charlotte, North Carolina 28204, United States
  • Local Institution
    Fargo, North Dakota 58102, United States
  • Local Institution
    Allentown, Pennsylvania 18103, United States
  • Local Institution
    Sioux Falls, South Dakota 57104, United States
  • Local Institution
    Vancouver, Washington 98684, United States
  • Local Institution
    Viedma, RIO Negro 8500, Argentina
  • Local Institution
    Buenos Aires, 1093, Argentina
  • Local Institution
    Caba, 1199, Argentina
  • Local Institution
    Ciudad Autonoma de Buenos Aires, 1426, Argentina
  • Local Institution
    Cordoba, 5000, Argentina
  • Local Institution
    Westmead, New South Wales 2145, Australia
  • Local Institution
    Heidelberg, Victoria 3084, Australia
  • Local Institution
    Malvern, Victoria 3144, Australia
  • Local Institution
    Melbourne, Victoria 3000, Australia
  • Local Institution
    Bedford Park, 5024, Australia
  • Local Institution
    Murdoch, 6150, Australia
  • Local Institution
    Fortaleza, Ceara 60430-230, Brazil
  • Local Institution
    Belo Horizonte, Minas Gerais 30130-090, Brazil
  • Local Institution
    Porto Alegre, RIO Grande DO SUL 90035-903, Brazil
  • Local Institution
    Barretos, SAO Paulo 14780-070, Brazil
  • Local Institution
    Jau, SAO Paulo 17210-080, Brazil
  • Local Institution
    Rio de Janeiro, 22793-080, Brazil
  • Local Institution
    Sao Paulo, 01246-000, Brazil
  • Local Institution
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Local Institution
    Hamilton, Ontario L8V 5C2, Canada
  • Local Institution
    Ottawa, Ontario K1H 8L6, Canada
  • Local Institution
    Toronto, Ontario M5B 1W8, Canada
  • Local Institution
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution
    Montreal, Quebec H4J 1C5, Canada
  • Local Institution
    Sherbrooke, Quebec J1H 5N4, Canada
  • Local Institution
    Santiago, Metropolitana 8330024, Chile
  • Local Institution
    Santiago, Metropolitana, Chile
  • Local Institution
    Medellin, Colombia
  • Local Institution
    Berlin, 13125, Germany
  • Local Institution
    Cologne, 50937, Germany
  • Local Institution
    Erlangen, 91054, Germany
  • Local Institution
    Essen, 45147, Germany
  • Local Institution
    Frankfurt am Main, 60488, Germany
  • Local Institution
    Freiburg, 79106, Germany
  • Local Institution
    Hamburg, 22763, Germany
  • Local Institution
    Hannover, 30625, Germany
  • Local Institution
    Jena, 07747, Germany
  • Local Institution
    Mainz, 55131, Germany
  • Local Institution
    Mannheim, 68167, Germany
  • Local Institution
    Marburg, 35043, Germany
  • Local Institution
    Paderborn, 33098, Germany
  • Local Institution
    Reutlingen, 72764, Germany
  • Local Institution
    Wiesbaden, 65199, Germany
  • Local Institution
    Bergamo, 24127, Italy
  • Local Institution
    Milano, 20133, Italy
  • Local Institution
    Napoli, 80131, Italy
  • Local Institution
    Reggio Emilia, 42100, Italy
  • Local Institution
    Tuxtla Gutierrez, Chiapas 29029, Mexico
  • Local Institution
    Mexico City, Distrito Federal 14080, Mexico
  • Local Institution
    ZONA Centro. LEON, Guanajuato 37000, Mexico
  • Local Institution
    Merida, Yucatan 97134, Mexico
  • Local Institution
    Aguascalientes, 20230, Mexico
  • Local Institution
    Lisboa, 1649-035, Portugal
  • Local Institution
    Porto, 4200-072, Portugal
  • Local Institution
    Rio Piedras, 00935, Puerto Rico
  • Local Institution
    Bucuresti, 022328, Romania
  • Local Institution
    Cluj-Napoca, 400015, Romania
  • Local Institution
    Craiova, 200347, Romania
  • Local Institution
    Floresti, 407280, Romania
  • Local Institution
    Badajoz, 06006, Spain
  • Local Institution
    Madrid, 28007, Spain
  • Local Institution
    Madrid, 28034, Spain
  • Local Institution
    Madrid, 28050, Spain
  • Local Institution
    Valencia, 46026, Spain
08

References and documents

Individual participant data

Plan to share: Yes — Individual patient level data from this study may be shared with qualified researchers, upon request, following the timelines and process detailed on https://www.bms.com/researchers-and-partners/independent-research/data-sharing-request-process.html

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2019; primary completion for Feb 2022, 27 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2018
First posted
Oct 12, 2018
StartEst.
Oct 31, 2019
Primary completionEst.
Feb 27, 2022
CompletionEst.
Sep 30, 2024
Last update
May 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03704077
Responsible party
Sponsor
First posted
Oct 12, 2018
Start date
Oct 31, 2019 (estimated)
Primary completion
Feb 27, 2022 (estimated)
Completion
Sep 30, 2024 (estimated)
Last update
May 19, 2020

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Relatlimab · Nivolumab · Paclitaxel

Start the discussion